WO2000060117A3 - Prediction des risques de pathologie interstitielle pulmonaire - Google Patents

Prediction des risques de pathologie interstitielle pulmonaire Download PDF

Info

Publication number
WO2000060117A3
WO2000060117A3 PCT/US2000/008492 US0008492W WO0060117A3 WO 2000060117 A3 WO2000060117 A3 WO 2000060117A3 US 0008492 W US0008492 W US 0008492W WO 0060117 A3 WO0060117 A3 WO 0060117A3
Authority
WO
WIPO (PCT)
Prior art keywords
interstitial lung
prediction
risk
lung disease
ild
Prior art date
Application number
PCT/US2000/008492
Other languages
English (en)
Other versions
WO2000060117A2 (fr
Inventor
Gordon W Duff
Giovine Francesco Saverio Di
Moria Whyte
Original Assignee
Interleukin Genetics Inc
Gordon W Duff
Giovine Francesco Saverio Di
Moria Whyte
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Interleukin Genetics Inc, Gordon W Duff, Giovine Francesco Saverio Di, Moria Whyte filed Critical Interleukin Genetics Inc
Priority to CA002367294A priority Critical patent/CA2367294A1/fr
Priority to AU41837/00A priority patent/AU779701B2/en
Priority to JP2000609606A priority patent/JP2002540801A/ja
Priority to EP00921536A priority patent/EP1192275A2/fr
Priority to IL14571400A priority patent/IL145714A0/xx
Publication of WO2000060117A2 publication Critical patent/WO2000060117A2/fr
Publication of WO2000060117A3 publication Critical patent/WO2000060117A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Abstract

L'invention concerne des méthodes et des kits nouveaux permettant de déterminer si un sujet est atteint d'une pathologie interstitielle pulmonaire ou s'il est susceptible de développer une telle pathologie, telle que la fibrose pulmonaire. L'invention concerne également des méthodes de traitement d'une pathologie interstitielle pulmonaire et des essais de criblage pour identifier de nouvelles thérapeutiques contre ces pathologies.
PCT/US2000/008492 1999-04-02 2000-03-31 Prediction des risques de pathologie interstitielle pulmonaire WO2000060117A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002367294A CA2367294A1 (fr) 1999-04-02 2000-03-31 Prediction des risques de pathologie interstitielle pulmonaire
AU41837/00A AU779701B2 (en) 1999-04-02 2000-03-31 Prediction of risk of interstitial lung disease
JP2000609606A JP2002540801A (ja) 1999-04-02 2000-03-31 間質性肺疾患の危険性の予測
EP00921536A EP1192275A2 (fr) 1999-04-02 2000-03-31 Prediction des risques de pathologie interstitielle pulmonaire
IL14571400A IL145714A0 (en) 1999-04-02 2000-03-31 Prediction of risk of interstitial lung disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28610899A 1999-04-02 1999-04-02
US09/286,108 1999-04-02

Publications (2)

Publication Number Publication Date
WO2000060117A2 WO2000060117A2 (fr) 2000-10-12
WO2000060117A3 true WO2000060117A3 (fr) 2002-02-07

Family

ID=23097113

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/008492 WO2000060117A2 (fr) 1999-04-02 2000-03-31 Prediction des risques de pathologie interstitielle pulmonaire

Country Status (6)

Country Link
EP (1) EP1192275A2 (fr)
JP (1) JP2002540801A (fr)
AU (1) AU779701B2 (fr)
CA (1) CA2367294A1 (fr)
IL (1) IL145714A0 (fr)
WO (1) WO2000060117A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002211566A1 (en) * 2000-10-10 2002-04-22 Grant W. Waterer Method for identifying increased risk of death from community acquired pneumonia
EP1455813B1 (fr) * 2001-12-18 2015-07-15 mondoBIOTECH AG Interferon gamma dans combinaison avec une puce de diagnostic medical pour une utilisation dans le traitement amélioré la fibrose pulmonaire idiopathique
US20030148288A1 (en) * 2002-02-01 2003-08-07 Yi-Wei Tang Colorimetric genetic test for clinically significant TNF polymorphism and methods of use thereof
BR0315344A (pt) * 2002-10-15 2005-08-23 Novartis Ag Métodos para prever edema como um efeito colateral do tratamento com drogas
WO2006100446A2 (fr) * 2005-03-23 2006-09-28 Astrazeneca Uk Limited Procede
EP1888779A4 (fr) * 2005-05-20 2009-06-10 Synergenz Bioscience Ltd Méthodes d'analyse de polymorphismes et leurs utilisations
EP4219760A3 (fr) * 2008-11-10 2023-09-06 Battelle Memorial Institute Procédés, compositions et dispositifs utilisant un microarn pour déterminer des états physiologiques
ES2660113T3 (es) * 2011-12-21 2018-03-20 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Procedimientos relacionados con la fibrosis pulmonar idiopática (FPI)
US9873920B2 (en) 2013-03-01 2018-01-23 Saitama Medical University Method for evaluating side-effect onset risk in anticancer drug treatment, including detecting MUC4 gene polymorphism

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021946A1 (fr) * 1992-04-30 1993-11-11 Synergen, Inc. Methodes de traitement des maladies induites par l'interleukine-1 et le facteur de necrose tumorale
WO1997025445A1 (fr) * 1996-01-12 1997-07-17 Cedars-Sinai Medical Center Techniques de depistage de la rectocolite hemorragique par detection d'un polymorphisme d'un antagoniste du recepteur de l'interleukine-1
WO1998054359A1 (fr) * 1997-05-29 1998-12-03 Gordon Duff Prediction d'une maladie inflammatoire associee aux polymorphismes des loci sur le gene de l'il-1
WO1999024615A2 (fr) * 1997-11-07 1999-05-20 Medical Science Systems, Inc. Diagnostics et therapies des maladies obstructives chroniques des voies respiratoires

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021946A1 (fr) * 1992-04-30 1993-11-11 Synergen, Inc. Methodes de traitement des maladies induites par l'interleukine-1 et le facteur de necrose tumorale
WO1997025445A1 (fr) * 1996-01-12 1997-07-17 Cedars-Sinai Medical Center Techniques de depistage de la rectocolite hemorragique par detection d'un polymorphisme d'un antagoniste du recepteur de l'interleukine-1
WO1998054359A1 (fr) * 1997-05-29 1998-12-03 Gordon Duff Prediction d'une maladie inflammatoire associee aux polymorphismes des loci sur le gene de l'il-1
WO1999024615A2 (fr) * 1997-11-07 1999-05-20 Medical Science Systems, Inc. Diagnostics et therapies des maladies obstructives chroniques des voies respiratoires

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FRANCIS ET AL.: "Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease", CIRCULATION, vol. 99, February 1999 (1999-02-01), pages 861 - 866, XP001030756 *
HUANG SONG-LIH ET AL: "Tumor necrosis factor-alpha gene polymorphism in chronic bronchitis.", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 156, no. 5, November 1997 (1997-11-01), pages 1436 - 1439, XP002180758, ISSN: 1073-449X *
MOFFATT MIRIAM F ET AL: "Tumour necrosis factor haplotypes and asthma.", HUMAN MOLECULAR GENETICS, vol. 6, no. 4, 1997, pages 551 - 554, XP002180759, ISSN: 0964-6906 *
WHYTE MOIRA ET AL: "Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-alpha gene polymorphisms.", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 162, no. 2 Part 1, August 2000 (2000-08-01), pages 755 - 758, XP002180760, ISSN: 1073-449X *

Also Published As

Publication number Publication date
WO2000060117A2 (fr) 2000-10-12
AU779701B2 (en) 2005-02-10
JP2002540801A (ja) 2002-12-03
CA2367294A1 (fr) 2000-10-12
EP1192275A2 (fr) 2002-04-03
IL145714A0 (en) 2002-07-25
AU4183700A (en) 2000-10-23

Similar Documents

Publication Publication Date Title
WO2000037679A3 (fr) Diagnostic et traitement d'une septicemie
AU2002257162A1 (en) Humanized antibodies
WO2001055327A3 (fr) Acides nucleiques, proteines et anticorps
HK1184534A1 (zh) 通過測定半乳糖苷凝集素- 或者血小板反應蛋白- 的水平鑒定具有發生心力衰竭風險的受試者的方法
AU5212199A (en) Methods and kits for diagnosing and determination of the predisposition of diseases
HK1061699A1 (en) Human anti timp-1 antibodies
WO2000060117A3 (fr) Prediction des risques de pathologie interstitielle pulmonaire
WO2000018899A3 (fr) Homologue d'enzyme de conversion d'angiotensine et son utilisation
ES2166822T3 (es) Procedimientos de seleccion de la enfermedad de crohn usando alelos de microsatelites de tnf.
WO2004020668A3 (fr) Methode de traitement du synovialome
DE60137513D1 (de) Methode zur Diagnose von oder zur Bestimmung des Risikos für Psychose beinhaltend die Bestimmung einer heterozygoten Mutation der Methylentetrahydrolfolatreduktase (MTHFR)
WO2003019196A3 (fr) Diagnostic et traitement de l'atherosclerose
AU2003242106A1 (en) Detection kit, assay plate to be used therein, detection method, evaluation method, polyclonal antibody of frog vitellogenin and procss for producing the same
AU1309601A (en) Novel protein and dna thereof
DE69924617D1 (de) Immunologische Bestimmung des hydrophoben Lungensurfaktantproteins SP-C
BR9815090A (pt) "moléculas de ácido nucléico correlacionadas com o fenótipo rhesus d fraco"
WO2002067766A8 (fr) Procedes et materiel d'evaluation des pathologies cardio-vasculaires
EP1097944A4 (fr) Anticorps specifique des domaines intracellulaires de la thyrosinephosphatase
GB0110036D0 (en) Methods
WO1999024615A3 (fr) Diagnostics et therapies des maladies obstructives chroniques des voies respiratoires
WO2005060627A3 (fr) Methodes permettant d'evaluer un risque de fracture osseuse non traumatique
WO2002027016A3 (fr) Gene intervenant dans l'absorption et l'excretion de sterol alimentaire et ses utilisations
WO2002074908A3 (fr) Methodes et reactifs de regulation de l'apoptose
WO2002044375A3 (fr) Compositions et methodes de diagnostic ou de traitement du psoriasis
WO2001081546A3 (fr) Genes, proteines cesert et composes de modulation de ceux-ci

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AU BR CA CN CZ HU IL JP KR MX NO NZ PL RU SG TR US YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2367294

Country of ref document: CA

Ref country code: CA

Ref document number: 2367294

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 609606

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000921536

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AU BR CA CN CZ HU IL JP KR MX NO NZ PL RU SG TR US YU ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWP Wipo information: published in national office

Ref document number: 2000921536

Country of ref document: EP